Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Dermatology

Date Submitted: Dec 14, 2022
Date Accepted: May 15, 2023
Date Submitted to PubMed: Aug 26, 2023

The final, peer-reviewed published version of this preprint can be found here:

Stevens-Johnson Syndrome in Adult Patient Secondary to COVID-19 Infection: Case Report

Khade D VI, shah A 2nd, Kharkar V 3rd

Stevens-Johnson Syndrome in Adult Patient Secondary to COVID-19 Infection: Case Report

JMIR Dermatol 2023;6:e45062

DOI: 10.2196/45062

PMID: 37632918

PMCID: 10335157

Stevens-Johnson Syndrome in adult patient secondary to COVID-19 infection

  • Dr.Pandharinath Khade VI; 
  • Avani shah 2nd; 
  • Vidya Kharkar 3rd

ABSTRACT

Coronavirus disease-19 (COVID-19) is global pandemic caused by a novel zoonotic RNA virus named (SARSCoV-2). It has varied with various of cutaneous manifestations associated with COVID-19 has been described, includes urticarial rash, confluent erythematous rash, papulovesicular exanthem, chilblain like acral pattern, livedo reticularis, purpuric “vasculitis” pattern. Here we are presenting a case of 45-year-old male presented with muco-cutaneous features of Steven–Johnson Syndrome.


 Citation

Please cite as:

Khade D VI, shah A 2nd, Kharkar V 3rd

Stevens-Johnson Syndrome in Adult Patient Secondary to COVID-19 Infection: Case Report

JMIR Dermatol 2023;6:e45062

DOI: 10.2196/45062

PMID: 37632918

PMCID: 10335157

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.